Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Athar Aziz is active.

Publication


Featured researches published by Athar Aziz.


The New England Journal of Medicine | 2013

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

Jyoti Nangalia; Gunes Gundem; Edward Avezov; Jingjin Li; Karoline Kollmann; Athar Aziz; Jonathan Hinton; Inigo Martincorena; P. Van Loo; Paola Guglielmelli; Patrick Tarpey; Keiran Raine; Stuart McLaren; M. Bianchi; Yvonne Silber; D. Dimitropoulou; David Bloxham; Laura Mudie; Mark Maddison; Ben Robinson; Clodagh Keohane; Cathy MacLean; Katherine L. Hill; Kim H. Orchard; Sudhir Tauro; Mel Greaves; David G. Bowen; David Ron; Elli Papaemmanuil

BACKGROUND Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge. METHODS We performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1345 hematologic cancers, 1517 other cancers, and 550 controls. We established phylogenetic trees using hematopoietic colonies. We assessed calreticulin subcellular localization using immunofluorescence and flow cytometry. RESULTS Exome sequencing identified 1498 mutations in 151 patients, with medians of 6.5, 6.5, and 13.0 mutations per patient in samples of polycythemia vera, essential thrombocythemia, and myelofibrosis, respectively. Somatic CALR mutations were found in 70 to 84% of samples of myeloproliferative neoplasms with nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other cancers. A total of 148 CALR mutations were identified with 19 distinct variants. Mutations were located in exon 9 and generated a +1 base-pair frameshift, which would result in a mutant protein with a novel C-terminal. Mutant calreticulin was observed in the endoplasmic reticulum without increased cell-surface or Golgi accumulation. Patients with myeloproliferative neoplasms carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels than patients with mutated JAK2. Mutation of CALR was detected in hematopoietic stem and progenitor cells. Clonal analyses showed CALR mutations in the earliest phylogenetic node, a finding consistent with its role as an initiating mutation in some patients. CONCLUSIONS Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2. (Funded by the Kay Kendall Leukaemia Fund and others.).


Science | 2009

MafB/c-Maf Deficiency Enables Self-Renewal of Differentiated Functional Macrophages

Athar Aziz; Erinn Soucie; Sandrine Sarrazin; Michael H. Sieweke

Self-Renewing Macrophages The capacity for self-renewal is associated with progenitor cell populations and is lost upon differentiation. Aziz et al. (p. 867) discovered an exception to this rule when mouse monocytes and macrophages deficient in the transcription factors MafB and c-Maf were cultured in the presence of the growth factor, macrophage colony-stimulating factor (M-CSF). Under these conditions, MafB/c-Maf–deficient cells were able to divide continuously while maintaining the phenotype and function of mature cells. Unexpectedly, when these in vitro–cultured cells were transferred into mice, they did not induce tumors, despite continuing to divide, but rather incorporated themselves into tissues and adopted normal macrophage functions. Suppression of two genes involved in the self-renewal capacity of inducible pluripotent stem cells, KLF4 and c-Myc, inhibited the ability of MafB/c-Maf–deficient macrophages to self-renew. Such long-term propagation of a differentiated cell population that does not result in transformation when reintroduced in vivo has exciting therapeutic potential. The absence of two transcription factors allows long-term propagation of a differentiated immune cell population that is nontumorigenic. In metazoan organisms, terminal differentiation is generally tightly linked to cell cycle exit, whereas the undifferentiated state of pluripotent stem cells is associated with unlimited self-renewal. Here, we report that combined deficiency for the transcription factors MafB and c-Maf enables extended expansion of mature monocytes and macrophages in culture without loss of differentiated phenotype and function. Upon transplantation, the expanded cells are nontumorigenic and contribute to functional macrophage populations in vivo. Small hairpin RNA inactivation shows that continuous proliferation of MafB/c-Maf deficient macrophages requires concomitant up-regulation of two pluripotent stem cell–inducing factors, KLF4 and c-Myc. Our results indicate that MafB/c-MafB deficiency renders self-renewal compatible with terminal differentiation. It thus appears possible to amplify functional differentiated cells without malignant transformation or stem cell intermediates.


Cell | 2009

MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells.

Sandrine Sarrazin; Noushine Mossadegh-Keller; Taro Fukao; Athar Aziz; Frédéric Mourcin; Louise K. Modis; Philippe Kastner; Susan Chan; Estelle Duprez; Claas Otto; Michael H. Sieweke

While hematopoietic stem cell (HSC) self-renewal is well studied, it remains unknown whether distinct control mechanisms enable HSC divisions that generate progeny cells with specific lineage bias. Here, we report that the monocytic transcription factor MafB specifically restricts the ability of M-CSF to instruct myeloid commitment divisions in HSCs. MafB deficiency specifically enhanced sensitivity to M-CSF and caused activation of the myeloid master-regulator PU.1 in HSCs in vivo. Single-cell analysis revealed that reduced MafB levels enabled M-CSF to instruct divisions producing asymmetric daughter pairs with one PU.1(+) cell. As a consequence, MafB(-/-) HSCs showed a PU.1 and M-CSF receptor-dependent competitive repopulation advantage specifically in the myelomonocytic, but not T lymphoid or erythroid, compartment. Lineage-biased repopulation advantage was progressive, maintained long term, and serially transplantable. Together, this indicates that an integrated transcription factor/cytokine circuit can control the rate of specific HSC commitment divisions without compromising other lineages or self-renewal.


Molecular and Cellular Biology | 2006

Development of Macrophages with Altered Actin Organization in the Absence of MafB

Athar Aziz; Peer Mohideen; Louise M. Kelly; Claas Otto; Youssef Bakri; Noushine Mossadegh; Sandrine Sarrazin; Michael H. Sieweke

ABSTRACT In the hematopoietic system the bZip transcription factor MafB is selectively expressed at high levels in monocytes and macrophages and promotes macrophage differentiation in myeloid progenitors, whereas a dominant-negative allele can inhibit this process. To analyze the requirement of MafB for macrophage development, we generated MafB-deficient mice and, due to their neonatal lethal phenotype, analyzed macrophage differentiation in vitro, in the embryo, and in reconstituted mice. Surprisingly we observed in vitro differentiation of macrophages from E14.5 fetal liver (FL) cells and E18.5 splenocytes. Furthermore we found normal numbers of F4/80+/Mac-1+ macrophages and monocytes in fetal liver, spleen, and blood as well as in bone marrow, spleen, and peritoneum of adult MafB−/− FL reconstituted mice. MafB−/− macrophages showed intact basic macrophage functions such as phagocytosis of latex beads or Listeria monocytogenes and nitric oxide production in response to lipopolysaccharide. By contrast, MafB−/− macrophages expressed increased levels of multiple genes involved in actin organization. Consistent with this, phalloidin staining revealed an altered morphology involving increased numbers of branched protrusions of MafB−/− macrophages in response to macrophage colony-stimulating factor. Together these data point to an unexpected redundancy of MafB function in macrophage differentiation and a previously unknown role in actin-dependent macrophage morphology.


Blood | 2014

JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease

Juan Li; David G. Kent; Anna L. Godfrey; Harriet Manning; Jyoti Nangalia; Athar Aziz; Edwin Chen; Kourosh Saeb-Parsy; Juergen Fink; Rachel Sneade; Tina L. Hamilton; Dean C. Pask; Yvonne Silber; Xiaodong Zhao; Cedric Ghevaert; Pentao Liu; Anthony R. Green

Genomic regions of acquired uniparental disomy (UPD) are common in malignancy and frequently harbor mutated oncogenes. Homozygosity for such gain-of-function mutations is thought to modulate tumor phenotype, but direct evidence has been elusive. Polycythemia vera (PV) and essential thrombocythemia (ET), 2 subtypes of myeloproliferative neoplasms, are associated with an identical acquired JAK2V617F mutation but the mechanisms responsible for distinct clinical phenotypes remain unclear. We provide direct genetic evidence and demonstrate that homozygosity for human JAK2V617F in knock-in mice results in a striking phenotypic switch from an ET-like to PV-like phenotype. The resultant erythrocytosis is driven by increased numbers of early erythroid progenitors and enhanced erythroblast proliferation, whereas reduced platelet numbers are associated with impaired platelet survival. JAK2V617F-homozygous mice developed a severe hematopoietic stem cell defect, suggesting that additional lesions are needed to sustain clonal expansion. Together, our results indicate that UPD for 9p plays a causal role in the PV phenotype in patients as a consequence of JAK2V617F homozygosity. The generation of a JAK2V617F allelic series of mice with a dose-dependent effect on hematopoiesis provides a powerful model for studying the consequences of mutant JAK2 homozygosity.


Clinical Epigenetics | 2013

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

Athar Aziz; E. Joanna Baxter; Carol Ann Edwards; Clara Yujing Cheong; Mitsuteru Ito; Anthony J. Bench; Rebecca Kelley; Yvonne Silber; Philip A. Beer; Keefe Chng; Marilyn B. Renfree; Kirsten McEwen; Dionne Gray; Jyoti Nangalia; Ghulam J. Mufti; Eva Hellström-Lindberg; Jean-Jacques Kiladjian; Mary Frances McMullin; Peter J. Campbell; Anne C. Ferguson-Smith; Anthony R. Green

Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primaterestricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/ SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprinted gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of genomic loss, and underline the complex molecular and cellular consequences of “simple” cancer-associated chromosome deletions.


Blood | 2013

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Charles Massie; E. Joanna Baxter; Francesca L. Nice; Gunes Gundem; David C. Wedge; Edward Avezov; Juan Li; Karoline Kollmann; David G. Kent; Athar Aziz; Anna L. Godfrey; Jonathan Hinton; Inigo Martincorena; Peter Van Loo; Amy V. Jones; Paola Guglielmelli; Patrick Tarpey; Heather P. Harding; John D Fitzpatrick; Calum T Goudie; Christina A. Ortmann; Stephen Loughran; Keiran Raine; David Jones; Adam Butler; Jon Teague; Sarah O'Meara; Stuart McLaren; Michele Bianchi; Yvonne Silber


Annals of Oncology | 2017

71PCALR mutations and their link with cellular calcium during megakaryocyte hyperplasia in MPNs

M. Morlan Mairal; P. Papadopoulos; J. Hetmanski; P.T. Caswell; M. Krstic-Demonacos; Athar Aziz


European Journal of Cancer | 2016

New insights of mutant calreticulin in myeloproliferative neoplasms

M. Morlan Mairal; Athar Aziz


Anticancer Research | 2016

Dibenzoyl-methane Derivatives as a Potential and Exciting New Therapy for the Treatment of Childhood Bone Cancer.

Eman Almelah; David P. T. Smith; Andrew Mcgown; Athar Aziz; Herman Potgieter; Patricia Ragazzon

Collaboration


Dive into the Athar Aziz's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Inigo Martincorena

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Jonathan Hinton

Wellcome Trust Sanger Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge